…
Bionik Laboratories Corp., a robotics company, engages in designing, developing, and commercializing physical rehabilitation technologies, prosthetics, and assisted robotic products. It offers InMotion Robots, which include a suite of robotic rehabilitation products; InMotion ARM, an evidence-based intelligent interactive rehabilitation technology that senses patient movements and limitations; InMotion ARM/HAND, which provides support for therapy involving reaching with grasp and release movements, and individual hand movements; and InMotion Connect platform that consists of a hardware device connected to the InMotion Robot, as well as a subscription to InMotion Connect Pulse. Bionik Laboratories Corp. was incorporated in 2010 and is headquartered in Watertown, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Bionik Laboratories Corp develops and commercializes robotic and assistive technologies for physical rehabilitation and mobility. Long-term growth drivers include aging populations, rising prevalence of neurologic and mobility impairments, and increasing interest in robotic solutions for clinical and home-based therapy, which may benefit demand and support gradual market expansion.
Key risks include limited liquidity and disclosure typical of Pink-sheet listings, execution and commercialization challenges, regulatory and reimbursement uncertainty, and likely need for additional financing that could dilute shareholders.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Income before tax | -4.95M | -10.41M | -13.62M | -25.02M | -10.56M |
| Net income | -13839.95M | -15.61M | -13.96M | -24.93M | -10.56M |
| Selling general administrative | 2.93M | 2.81M | 4.57M | 5.98M | 5.24M |
| Selling and marketing expenses | 1.98M | 1.92M | 1.02M | 2.17M | 2.34M |
| Gross profit | 0.99M | 0.95M | 0.92M | 1.26M | 1.62M |
| Reconciled depreciation | 0.06M | 0.10M | 0.19M | 0.38M | 0.35M |
| Ebit | -4.83M | -4.77M | -6.16M | -11.25M | -7.29M |
| Ebitda | -4.78M | -4.38M | -6.03M | -10.87M | -6.94M |
| Depreciation and amortization | 0.05M | 0.39M | 0.12M | 0.38M | 0.35M |
| Operating income | -4.83M | -4.77M | -6.16M | -11.25M | -7.29M |
| Other operating expenses | 6.63M | 6.05M | 7.35M | 13.32M | 12.73M |
| Interest expense | 0.11M | 0.83M | 0.41M | 0.00M | 3.27M |
| Interest income | - | - | - | 0.10M | 0.07M |
| Net interest income | -0.11M | -0.83M | -0.41M | 0.00M | -3.27M |
| Income tax expense | 13835.00M | 5.20M | 0.34M | -0.08M | -0.00M |
| Total revenue | 1.81M | 1.27M | 1.19M | 2.15M | 3.25M |
| Total operating expenses | 5.81M | 5.73M | 7.08M | 12.42M | 11.10M |
| Cost of revenue | 0.82M | 0.32M | 0.27M | 0.89M | 1.63M |
| Total other income expense net | -0.12M | -5.64M | -7.47M | -13.77M | -3.27M |
| Net income from continuing ops | -4.95M | -10.41M | -13.62M | -25.02M | -10.56M |
| Net income applicable to common shares | -4.95M | -10.41M | -13.62M | -25.02M | -10.56M |
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Total assets | 3.36M | 4.68M | 8.79M | 18.52M | 30.68M |
| Intangible assets | 0.03M | - | 0.98M | 1.45M | 4.43M |
| Other current assets | 862603.00M | 1.13M | 1680557.00M | 1.59M | 1.37M |
| Total liab | 5.00M | 1.75M | 5.51M | 5.20M | 3.27M |
| Total stockholder equity | -1.64M | 2.93M | 3.28M | 13.32M | 27.41M |
| Other current liab | 1.39M | 0.87M | 0.76M | 1.65M | 1.65M |
| Common stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.00M |
| Capital stock | 0.01M | 0.01M | 0.01M | 0.01M | 0.00M |
| Retained earnings | -100.35M | -95.40M | -84.99M | -71.37M | -46.36M |
| Other liab | 0.30M | 0.26M | 0.30M | 0.42M | - |
| Good will | 0.10M | 0.00M | 4.28M | 11.09M | 22.31M |
| Other assets | 0.01M | - | - | - | - |
| Cash | 0.43M | 1.99M | 0.61M | 2.27M | 0.45M |
| Total current liabilities | 2.31M | 1.49M | 4.10M | 5.20M | 3.27M |
| Current deferred revenue | 0.34M | 0.31M | 0.27M | 0.62M | 0.47M |
| Net debt | 1.98M | -1.99M | 3.11M | -0.19M | -0.45M |
| Short term debt | 0.02M | - | 2.61M | 2.08M | - |
| Short long term debt | - | - | 2.61M | 2.08M | - |
| Short long term debt total | 2.41M | - | 3.72M | 2.08M | - |
| Other stockholder equity | 98.67M | 98.29M | 88.23M | 84.64M | 73.72M |
| Property plant equipment | 0.44M | 0.09M | 0.09M | 0.15M | 0.19M |
| Total current assets | 2.78M | 4.58M | 3.43M | 5.83M | 3.75M |
| Net tangible assets | -1.77M | 2.93M | -1.98M | 0.78M | 0.67M |
| Net receivables | 0.45M | 0.27M | 2.13M | 0.91M | 2.90M |
| Long term debt | 2.16M | - | 1.11M | - | - |
| Inventory | 1.03M | 1.19M | 0.69M | 1.06M | 0.41M |
| Accounts payable | 0.56M | 0.31M | 0.45M | 0.86M | 1.15M |
| Accumulated other comprehensive income | 0.03M | 0.03M | 0.04M | 0.04M | 0.04M |
| Common stock total equity | - | - | - | 0.01M | 0.00M |
| Non currrent assets other | 0.01M | - | - | - | 26.93M |
| Non current assets total | 0.58M | 0.09M | 5.35M | 12.69M | 26.93M |
| Capital lease obligations | 0.26M | - | - | - | - |
| Breakdown | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-03-31 | 2022-03-31 | 2021-03-31 | 2020-03-31 | 2019-03-31 |
| Investments | -0.22M | -0.01M | - | -0.16M | -0.10M |
| Change to liabilities | 0.34M | -0.15M | -0.45M | -0.14M | 0.77M |
| Total cashflows from investing activities | -0.22M | -0.01M | -0.01M | -0.16M | -0.10M |
| Net borrowings | 2.05M | 5.55M | 2.96M | 11.05M | 9.27M |
| Total cash from financing activities | 2.05M | 5.55M | 2.96M | 11.05M | 9.27M |
| Change to operating activities | 0.78M | 0.66M | 0.12M | -0.28M | -0.80M |
| Net income | -4.95M | -10.41M | -13.62M | -25.02M | -10.56M |
| Change in cash | -1.56M | 1.38M | -1.66M | 1.82M | -0.06M |
| Begin period cash flow | 1.99M | 0.61M | 2.27M | 0.45M | 0.51M |
| End period cash flow | 0.43M | 1.99M | 0.61M | 2.27M | 0.45M |
| Total cash from operating activities | -3.39M | -4.15M | -4.62M | -9.06M | -9.23M |
| Depreciation | 0.06M | 0.10M | 0.19M | 0.38M | 0.35M |
| Dividends paid | - | - | - | - | 0.00M |
| Change to inventory | 0.08M | -0.54M | 0.33M | -0.65M | -0.17M |
| Change to account receivables | -0.18M | 0.18M | 0.40M | 0.51M | -1.29M |
| Other cashflows from financing activities | 2.05M | 5.55M | 2.96M | 11.57M | 9.32M |
| Change to netincome | 0.48M | 6.02M | 8.41M | 16.14M | 2.46M |
| Capital expenditures | 50185.00M | 0.01M | 0.01M | 0.16M | 0.10M |
| Change in working capital | 1.01M | 0.14M | 0.40M | -0.57M | -1.49M |
| Stock based compensation | 0.38M | 0.38M | 0.82M | 1.78M | 1.35M |
| Other non cash items | 0.11M | 5.63M | 0.41M | 0.18M | 1.14M |
| Free cash flow | 50181.61M | -4.16M | -4.62M | -9.22M | -9.33M |
Sector: Healthcare Industry: Medical Care Facilities
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BNKL Bionik Laboratories Corp |
- -% |
0.00 | - | - | 0.00 | 8.04 | 3.64 | -1.10 |
| HCA HCA Healthcare, Inc. |
15.19 3.30% |
475.52 | 14.27 | 13.46 | 1.21 | 291.34 | 1.83 | 8.99 |
| THC Tenet Healthcare Corporation |
-0.10 0.04% |
263.49 | 10.08 | 12.66 | 0.96 | 4.57 | 1.43 | 5.80 |
| FSNUY Fresenius SE & Co KGaA ADR |
-0.22 1.52% |
14.00 | 16.87 | 9.44 | 0.42 | 0.78 | 0.79 | 5.37 |
| JDHIY JD Health International Inc |
1.31 30.75% |
5.57 | 62.50 | 35.97 | 0.30 | 2.32 | 0.16 | 3.90 |
Bionik Laboratories Corp., a robotics company, engages in designing, developing, and commercializing physical rehabilitation technologies, prosthetics, and assisted robotic products. It offers InMotion Robots, which include a suite of robotic rehabilitation products; InMotion ARM, an evidence-based intelligent interactive rehabilitation technology that senses patient movements and limitations; InMotion ARM/HAND, which provides support for therapy involving reaching with grasp and release movements, and individual hand movements; and InMotion Connect platform that consists of a hardware device connected to the InMotion Robot, as well as a subscription to InMotion Connect Pulse. Bionik Laboratories Corp. was incorporated in 2010 and is headquartered in Watertown, Massachusetts.
80 Coolidge Hill Road, Watertown, MA, United States, 02472
617 926 4800
12
| Name | Title | Year Born |
|---|---|---|
| Mr. Richard Paul Russo Jr., CPA | CEO, Pres & Director | 1980 |
| Mr. Michal Prywata | Co-Founder & Director | 1991 |
| Mr. Daniel Gonsalves CPA | Exec. VP & CFO | 1983 |
| Mr. John Smathers | Director of Operations | NA |
| Mr. Mark Eiseman | Sales Director | NA |
| Mr. Richard Paul Russo Jr., CPA | CEO, President & Director | 1981 |
| Mr. Daniel Gonsalves CPA | Executive VP & CFO | 1984 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.